Core D: Neuropathology Core
核心 D:神经病理学核心
基本信息
- 批准号:10261112
- 负责人:
- 金额:$ 24.81万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-01 至 2026-06-30
- 项目状态:未结题
- 来源:
- 关键词:Advisory CommitteesAlzheimer&aposs DiseaseAlzheimer&aposs disease related dementiaAreaAutopsyBasic ScienceBiologicalBiological MarkersBrainClinicalClinical DataClinical ResearchCollaborationsCollectionCommunitiesCountryDNA LibraryDataDatabasesDementiaDiagnosticDiagnostic ServicesDiseaseEducational ActivitiesEvaluationFamily CaregiverFreezingFutureGoalsHealth ProfessionalHispanicsInstitutionInvestigationLatinoMichiganMicroscopyNerve DegenerationParticipantPathogenesisPatientsPhysiciansPlasmaPractice GuidelinesProceduresReagentRecruitment ActivityResearchResearch ActivityResearch PersonnelResearch Project GrantsResource SharingResourcesSamplingSerumStandardizationTechnologyTherapeuticTissue BanksTissuesTrainingUniversitiesWhole BloodWorkbrain dysfunctionbrain tissuecohortdata analysis pipelinedata managementeducation researchinnovationinnovative technologiesneuropathologynext generationoutreach servicesprofession allied to medicinetranslational study
项目摘要
ABSTRACT – CORE D: NEUROPATHOLOGY CORE
The Neuropathology Core (NC) will capitalize on the longstanding, actively recruiting University of Michigan (U-
M) Brain Bank and more than 35 years of patient clinical characterization by Alzheimer’s disease (AD)
researchers to advance the Michigan ADRC's central theme: to identify, understand and modulate the non-β-
amyloid factors contributing to brain dysfunction and neurodegeneration in AD and related dementias (ADRD).
The overall goal of the NC is to facilitate innovative research into the biological mechanisms of dementia by
providing essential reagents, expertise, and access to technologies for investigators at U-M, Michigan State
University, and Wayne State University, and to ADRCs and investigators across the country. Studies of ADRD
will be facilitated by the integrated efforts of the NC, Clinical Core, Biomarker Core, and Data Management and
Statistical Core to collect and properly characterize post-mortem material and associated antemortem
biospecimens and clinical data from ADRC participants. The NC will provide postmortem material and other
biospecimens to investigators while following the best practice guidelines delineated by the 2014 NIA
biospecimen task force for the evaluation, banking and distribution of brain tissue and biospecimens.
Leveraging the diverse expertise of NC investigators in neurodegenerative proteinopathies and a high-content
automated microscopy shared resource, the NC also will facilitate innovative research into the biological
mechanisms of dementia by providing essential reagents, expertise, and access to technologies for
investigators. To accomplish these goals, the NC will pursue the following aims: 1) grow and maintain a brain
bank with well-characterized frozen and fixed tissue, 2) provide accurate, detailed, and standardized
neuropathological evaluation, 3) distribute banked tissue and biospecimens, 4) contribute neuropathologic data
to the National Alzheimer’s Coordinating Center (NACC), 5) support researchers studying AD and related
dementias by providing access to innovative technologies, and 6) educate trainees about the neuropathologic
assessment of dementia. Through these aims, the NC will greatly facilitate basic and translational studies of
the dementias, expand the research community actively engaged in this work, and help build new
collaborations for future discoveries.
摘要 - 核心D:神经病理学核心
神经病理学核心(NC)将利用长期以来招募密歇根大学(U-
m)大脑库和经阿尔茨海默氏病(AD)的35年以上的患者临床表征
研究人员推进密歇根州ADRC的中心主题:识别,理解和调节非β--
在AD和相关痴呆症(ADRD)中导致脑功能障碍和神经退行性的淀粉样因子。
NC的总体目标是促进对痴呆生物学机制的创新研究
为U-M,密歇根州U-M的调查人员提供基本试剂,专业知识和获取技术的访问
大学和韦恩州立大学,以及全国各地的ADRC和研究人员。 ADRD的研究
NC,临床核心,生物标志物核心和数据管理的综合努力将准备
统计核心要收集并正确地表征验尸材料和相关的国歌
来自ADRC参与者的生物测量和临床数据。 NC将提供验尸材料和其他
在遵循2014年NIA划定的最佳实践指南的同时,调查人员的生物测量
用于评估,银行和分布的脑组织和生物晶体的生物测量工作组。
利用NC研究者在神经退行性蛋白质病和高质量方面的不同专业知识
自动显微镜共享资源,NC还将促进对生物学的创新研究
通过提供基本试剂,专业知识和获取技术的痴呆机制
调查人员。为了实现这些目标,NC将追求以下目的:1)成长并保持大脑
带有良好特征的冷冻和固定组织的库,2)提供准确,详细和标准化
神经病理学评估,3)分布式的银行组织和生物测量,4)贡献神经病理学数据
到国家阿尔茨海默氏症协调中心(NACC),5)支持研究广告及相关的研究人员
痴呆症通过提供创新技术的访问和6)教育人士有关神经病理学的教育
评估痴呆症。通过这些目标,北卡罗来纳州将极大地促进基础和翻译的研究
痴呆症,扩大研究社区积极从事这项工作,并帮助建立新的
未来发现的合作。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ANDREW P LIEBERMAN其他文献
ANDREW P LIEBERMAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ANDREW P LIEBERMAN', 18)}}的其他基金
Therapeutic Targets for Niemann-Pick Type C Neurodegeneration
尼曼-匹克 C 型神经变性的治疗靶点
- 批准号:
10907065 - 财政年份:2021
- 资助金额:
$ 24.81万 - 项目类别:
Mechanisms of neuromuscular degeneration in SBMA
SBMA 神经肌肉变性的机制
- 批准号:
10471367 - 财政年份:2021
- 资助金额:
$ 24.81万 - 项目类别:
Therapeutic targets for Niemann-Pick type C neurodegeneration
尼曼-皮克 C 型神经变性的治疗靶点
- 批准号:
10271742 - 财政年份:2021
- 资助金额:
$ 24.81万 - 项目类别:
Mechanisms of neuromuscular degeneration in SBMA
SBMA 神经肌肉变性的机制
- 批准号:
10290437 - 财政年份:2021
- 资助金额:
$ 24.81万 - 项目类别:
Therapeutic Targets for Niemann-Pick Type C Neurodegeneration
尼曼-匹克 C 型神经变性的治疗靶点
- 批准号:
10468243 - 财政年份:2021
- 资助金额:
$ 24.81万 - 项目类别:
相似海外基金
Racial/Ethnic Disparities in Health Care and Challenges in Insurance Plan Choices among Older People with Alzheimer’s Disease and Related Dementia: A Mixed Methods Study of Medicare Options
患有阿尔茨海默病和相关痴呆症的老年人在医疗保健方面的种族/民族差异以及保险计划选择的挑战:医疗保险选项的混合方法研究
- 批准号:
10723148 - 财政年份:2023
- 资助金额:
$ 24.81万 - 项目类别:
ACTS (AD Clinical Trial Simulation): Developing Advanced Informatics Approaches for an Alzheimer's Disease Clinical Trial Simulation System
ACTS(AD 临床试验模拟):为阿尔茨海默病临床试验模拟系统开发先进的信息学方法
- 批准号:
10753675 - 财政年份:2023
- 资助金额:
$ 24.81万 - 项目类别: